Mesa Laboratories (MLAB) Financials

$119.06 +3.66 (+3.17%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$118.71 -0.35 (-0.29%)

As of 05:00 AM Eastern

Annual Income Statements for Mesa Laboratories

This table shows Mesa Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	3/31/2022	3/31/2023	3/31/2024
Net Income / (Loss) Attributable to Common Shareholders	1.87	0.93	-254
Consolidated Net Income / (Loss)	1.87	0.93	-254
Net Income / (Loss) Continuing Operations	1.87	0.93	-254
Total Pre-Tax Income	3.57	-0.39	-276
Total Operating Income	4.70	3.32	-272
Total Gross Profit	109	134	133
Total Revenue	184	219	216
Operating Revenue	184	219	216
Total Cost of Revenue	75	85	83
Operating Cost of Revenue	75	85	83
Total Operating Expenses	104	130	405
Selling, General & Admin Expense	89	110	111
Research & Development Expense	16	20	19
Impairment Charge	0.00	0.00	275
Total Other Income / (Expense), net	-1.13	-3.71	-3.57
Interest Expense	3.89	4.77	5.70
Other Income / (Expense), net	2.76	1.06	2.12
Income Tax Expense	1.70	-1.32	-21
Basic Earnings per Share	$0.36	$0.17	($47.20)
Weighted Average Basic Shares Outstanding	5.21M	5.32M	5.39M
Diluted Earnings per Share	$0.35	$0.17	($47.20)
Weighted Average Diluted Shares Outstanding	5.34M	5.36M	5.39M
Weighted Average Basic & Diluted Shares Outstanding	5.27M	5.37M	5.41M
Cash Dividends to Common per Share	$0.64	$0.64	$0.64

This table shows Mesa Laboratories' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	6/30/2022	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-1.44	1.31	0.45	0.61	-0.55	-1.23	2.12	-255	3.39	3.43	-1.68
Consolidated Net Income / (Loss)	-1.44	1.31	0.45	0.61	-0.55	-1.23	2.12	-255	3.39	3.43	-1.68
Net Income / (Loss) Continuing Operations	-1.44	1.31	0.45	0.61	-0.55	-1.23	2.12	-255	3.39	3.43	-1.68
Total Pre-Tax Income	-5.41	3.38	1.92	-0.28	-0.94	-1.33	1.95	-275	3.91	3.81	-2.22
Total Operating Income	-4.59	4.00	3.40	0.52	-0.66	-0.06	-0.07	-271	5.58	3.51	5.78
Total Gross Profit	31	36	33	33	31	32	33	37	37	35	40
Total Revenue	50	59	54	56	51	53	53	59	58	58	63
Operating Revenue	50	59	54	56	51	53	53	59	58	58	63
Total Cost of Revenue	19	22	22	22	19	21	20	22	21	22	23
Operating Cost of Revenue	19	22	22	22	19	21	20	22	21	22	23
Total Operating Expenses	36	32	29	33	32	32	33	308	32	32	34
Selling, General & Admin Expense	30	27	25	28	27	27	29	28	27	27	29
Research & Development Expense	5.70	4.99	4.80	5.00	4.81	4.99	4.29	5.20	4.74	4.63	5.05
Total Other Income / (Expense), net	-0.82	-0.61	-1.49	-0.79	-0.27	-1.27	2.01	-4.05	-1.68	0.30	-8.00
Interest Expense	1.01	1.21	1.16	1.38	1.05	0.91	1.86	1.89	-0.36	3.02	2.84
Other Income / (Expense), net	0.20	0.60	-0.32	0.59	0.78	-0.36	3.87	-2.16	-2.03	3.32	-5.15
Income Tax Expense	-3.97	2.08	1.47	-0.89	-0.39	-0.10	-0.17	-21	0.52	0.38	-0.54
Basic Earnings per Share	($0.27)	$0.25	$0.08	$0.11	($0.10)	($0.23)	$0.39	($47.26)	$0.63	$0.63	($0.31)
Weighted Average Basic Shares Outstanding	5.27M	5.32M	5.34M	5.32M	5.37M	5.39M	5.39M	5.39M	5.40M	5.41M	5.43M
Diluted Earnings per Share	($0.27)	$0.24	$0.08	$0.12	($0.10)	($0.23)	$0.39	($47.26)	$0.62	$0.63	($0.31)
Weighted Average Diluted Shares Outstanding	5.27M	5.36M	5.36M	5.36M	5.37M	5.39M	5.40M	5.39M	5.42M	5.47M	5.43M
Weighted Average Basic & Diluted Shares Outstanding	5.32M	5.34M	5.35M	5.37M	5.38M	5.39M	5.39M	5.41M	5.41M	5.43M	5.43M
Cash Dividends to Common per Share	$0.16	$0.16	$0.16	$0.16	$0.16	$0.16	$0.16	$0.16	$0.16	$0.16	$0.16

This table details how cash moves in and out of Mesa Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	3/31/2022	3/31/2023	3/31/2024
Net Change in Cash & Equivalents	-215	-16	-4.70
Net Cash From Operating Activities	39	28	44
Net Cash From Continuing Operating Activities	39	28	44
Net Income / (Loss) Continuing Operations	1.87	0.93	-254
Consolidated Net Income / (Loss)	1.87	0.93	-254
Depreciation Expense	3.26	4.31	4.23
Amortization Expense	29	29	29
Non-Cash Adjustments To Reconcile Net Income	12	15	288
Changes in Operating Assets and Liabilities, net	-7.06	-21	-22
Net Cash From Investing Activities	-305	-9.49	-81
Net Cash From Continuing Investing Activities	-305	-9.49	-81
Purchase of Property, Plant & Equipment	-4.43	-4.54	-2.57
Acquisitions	-301	-4.95	-79
Net Cash From Financing Activities	53	-33	33
Net Cash From Continuing Financing Activities	53	-33	33
Repayment of Debt	-21	-36	-34
Payment of Dividends	-3.34	-3.41	-3.45
Issuance of Debt	70	0.00	71
Other Financing Activities, net	7.15	6.08	-0.37
Other Net Changes in Cash	-1.09	-1.60	-0.36
Cash Interest Paid	2.76	3.49	4.65
Cash Income Taxes Paid	3.05	1.36	4.59

This table details how cash moves in and out of Mesa Laboratories' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	6/30/2022	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-5.60	-11	-6.28	6.81	-0.53	3.24	-7.39	-0.01	0.26	-4.14	6.62
Net Cash From Operating Activities	-2.81	11	7.72	13	9.94	9.78	12	13	10	5.27	18
Net Cash From Continuing Operating Activities	-2.81	11	7.72	13	9.94	9.78	12	13	10	5.27	18
Net Income / (Loss) Continuing Operations	-1.44	1.31	0.45	0.61	-0.55	-1.23	2.12	-255	3.39	3.43	-1.68
Consolidated Net Income / (Loss)	-1.44	1.31	0.45	0.61	-0.55	-1.23	2.12	-255	3.39	3.43	-1.68
Depreciation Expense	8.13	8.06	-13	1.12	0.91	0.91	1.07	1.33	1.40	1.52	1.11
Amortization Expense	-	-	-	7.25	7.22	7.19	7.98	6.19	4.84	5.00	4.39
Non-Cash Adjustments To Reconcile Net Income	3.66	3.05	3.71	4.11	3.48	4.27	0.47	280	1.14	1.33	11
Changes in Operating Assets and Liabilities, net	-13	-1.86	-5.02	-0.56	-1.13	-1.36	-0.10	-20	-0.34	-6.01	3.56
Net Cash From Investing Activities	-0.23	-1.64	-6.60	-1.03	-0.27	-0.63	-81	0.43	-0.89	-1.79	-0.81
Net Cash From Continuing Investing Activities	-0.23	-1.64	-6.60	-1.03	-0.27	-0.63	-81	0.43	-0.89	-1.79	-0.81
Purchase of Property, Plant & Equipment	-0.23	-1.64	-1.65	-1.03	-0.27	-0.63	-1.13	-0.54	-0.89	-1.79	-0.81
Net Cash From Financing Activities	-1.41	-19	-8.88	-4.39	-9.52	-5.56	61	-13	-9.11	-8.61	-11
Net Cash From Continuing Financing Activities	-1.41	-19	-8.88	-4.39	-9.52	-5.56	61	-13	-9.11	-8.61	-11
Repayment of Debt	-2.00	-20	-8.00	-6.00	-8.66	-4.70	-9.29	-12	-82	-7.74	-9.73
Payment of Dividends	-0.84	-0.85	-0.86	-0.86	-0.86	-0.86	-0.86	-0.86	-0.86	-0.87	-0.87
Effect of Exchange Rate Changes	-1.16	-1.64	-	-	-0.68	-	-	-	-0.18	0.99	-0.41

This table presents Mesa Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	3/31/2022	3/31/2023	3/31/2024
Total Assets	707	662	447
Total Current Assets	124	119	109
Cash & Equivalents	49	33	28
Accounts Receivable	41	43	39
Inventories, net	25	35	33
Prepaid Expenses	9.14	8.87	9.41
Plant, Property, & Equipment, net	29	28	32
Total Noncurrent Assets	554	515	306
Goodwill	291	286	180
Intangible Assets	250	217	114
Noncurrent Deferred & Refundable Income Taxes	1.32	1.08	1.29
Other Noncurrent Operating Assets	12	10	11
Total Liabilities & Shareholders' Equity	707	662	447
Total Liabilities	314	268	301
Total Current Liabilities	48	43	44
Short-Term Debt	-	-	0.00
Accounts Payable	7.90	6.13	6.04
Accrued Expenses	12	12	13
Current Deferred Revenue	14	16	15
Current Employee Benefit Liabilities	15	9.43	9.94
Total Noncurrent Liabilities	266	225	257
Long-Term Debt	218	183	222
Noncurrent Deferred & Payable Income Tax Liabilities	39	34	20
Other Noncurrent Operating Liabilities	7.92	7.69	16
Total Equity & Noncontrolling Interests	394	393	145
Total Preferred & Common Equity	394	393	145
Total Common Equity	394	393	145
Common Stock	313	332	344
Retained Earnings	77	74	-183
Accumulated Other Comprehensive Income / (Loss)	3.67	-13	-15

This table presents Mesa Laboratories' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	6/30/2022	9/30/2022	12/31/2022	6/30/2023	9/30/2023	12/31/2023	6/30/2024	9/30/2024	12/31/2024
Total Assets	686	656	663	643	637	742	440	454	437
Total Current Assets	128	116	114	115	118	118	107	108	111
Cash & Equivalents	44	32	26	32	36	28	28	24	31
Accounts Receivable	42	42	42	36	36	36	36	40	39
Inventories, net	27	28	34	36	33	36	32	30	28
Prepaid Expenses	16	14	12	11	13	18	11	14	13
Plant, Property, & Equipment, net	28	28	28	28	29	32	31	32	32
Total Noncurrent Assets	530	512	521	500	491	592	302	314	295
Goodwill	284	278	286	284	283	346	180	184	177
Intangible Assets	235	222	223	205	198	233	109	109	98
Noncurrent Deferred & Refundable Income Taxes	0.69	0.65	0.71	1.08	1.05	1.09	1.28	1.33	1.24
Other Noncurrent Operating Assets	10	11	11	9.62	8.95	12	12	20	18
Total Liabilities & Shareholders' Equity	686	656	663	643	637	742	440	454	437
Total Liabilities	305	282	276	255	249	339	290	293	282
Total Current Liabilities	44	42	42	39	40	44	55	153	156
Short-Term Debt	-	-	-	-	-	-	3.75	101	101
Accounts Payable	7.56	7.74	6.29	5.59	4.81	4.55	5.66	5.99	4.09
Accrued Expenses	12	12	13	11	12	16	22	23	22
Current Deferred Revenue	15	14	15	15	14	14	15	14	15
Current Employee Benefit Liabilities	9.40	7.48	8.13	7.27	8.35	9.38	8.34	9.19	14
Total Noncurrent Liabilities	261	240	234	216	210	295	235	139	126
Long-Term Debt	217	197	189	176	171	233	208	104	95
Noncurrent Deferred & Payable Income Tax Liabilities	37	37	37	34	33	44	20	21	19
Other Noncurrent Operating Liabilities	7.34	6.83	8.17	6.76	5.44	17	6.58	15	12
Total Equity & Noncontrolling Interests	380	374	387	388	388	403	151	161	155
Total Preferred & Common Equity	380	374	387	388	388	403	151	161	155
Total Common Equity	380	374	387	388	388	403	151	161	155
Common Stock	318	325	327	334	338	341	346	350	353
Retained Earnings	74	75	74	73	71	72	-181	-178	-181
Accumulated Other Comprehensive Income / (Loss)	-12	-26	-14	-19	-21	-9.84	-14	-9.67	-17

This table displays calculated financial ratios and metrics derived from Mesa Laboratories' official financial filings.

Metric	2022	2023	2024
Period end date	3/31/2022	3/31/2023	3/31/2024
Growth Metrics	-	-	-
Revenue Growth	37.63%	18.85%	-1.32%
EBITDA Growth	45.15%	-6.19%	-732.14%
EBIT Growth	-27.77%	-41.27%	-6,261.86%
NOPAT Growth	-85.99%	-5.59%	-8,295.03%
Net Income Growth	-42.85%	-50.29%	-27,438.28%
EPS Growth	-45.31%	-51.43%	-27,864.71%
Operating Cash Flow Growth	5.80%	-28.66%	57.71%
Free Cash Flow Firm Growth	-3,325.63%	107.82%	-31.87%
Invested Capital Growth	95.40%	-3.37%	-37.69%
Revenue Q/Q Growth	12.80%	-1.48%	1.56%
EBITDA Q/Q Growth	0.19%	-6.12%	-720.16%
EBIT Q/Q Growth	-44.50%	-0.66%	-5,973.61%
NOPAT Q/Q Growth	-69.63%	23.28%	-99,197.45%
Net Income Q/Q Growth	-75.30%	163.48%	-26,919.20%
EPS Q/Q Growth	-75.86%	158.62%	-26,322.22%
Operating Cash Flow Q/Q Growth	-9.71%	12.99%	0.83%
Free Cash Flow Firm Q/Q Growth	-3.82%	-16.46%	125.13%
Invested Capital Q/Q Growth	-1.91%	-1.15%	-44.24%
Profitability Metrics	-	-	-
Gross Margin	59.18%	61.02%	61.64%
EBITDA Margin	21.69%	17.12%	-109.70%
Operating Margin	2.55%	1.52%	-125.85%
EBIT Margin	4.05%	2.00%	-124.87%
Profit (Net Income) Margin	1.02%	0.42%	-117.60%
Tax Burden Percent	52.35%	-239.07%	92.24%
Interest Burden Percent	47.92%	-8.88%	102.11%
Effective Tax Rate	47.65%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.58%	0.42%	-43.15%
ROIC Less NNEP Spread (ROIC-NNEP)	-1.74%	-0.45%	-80.26%
Return on Net Nonoperating Assets (RNNOA)	-0.11%	-0.18%	-51.21%
Return on Equity (ROE)	0.47%	0.24%	-94.36%
Cash Return on Invested Capital (CROIC)	-64.01%	3.85%	3.29%
Operating Return on Assets (OROA)	1.14%	0.64%	-48.70%
Return on Assets (ROA)	0.29%	0.14%	-45.87%
Return on Common Equity (ROCE)	0.47%	0.24%	-94.36%
Return on Equity Simple (ROE_SIMPLE)	0.48%	0.24%	-174.87%
Net Operating Profit after Tax (NOPAT)	2.46	2.32	-190
NOPAT Margin	1.34%	1.06%	-88.10%
Net Nonoperating Expense Percent (NNEP)	2.32%	0.87%	37.11%
Cost of Revenue to Revenue	40.82%	38.98%	38.36%
SG&A Expenses to Revenue	48.08%	50.16%	51.57%
R&D to Revenue	8.55%	9.35%	8.93%
Operating Expenses to Revenue	56.63%	59.51%	187.49%
Earnings before Interest and Taxes (EBIT)	7.46	4.38	-270
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	40	38	-237
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	3.36	2.36	4.07
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00
Price to Revenue (P/Rev)	7.18	4.23	2.73
Price to Earnings (P/E)	707.10	997.39	0.00
Dividend Yield	0.25%	0.37%	0.58%
Earnings Yield	0.14%	0.10%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.65	1.98	2.32
Enterprise Value to Revenue (EV/Rev)	8.09	4.92	3.63
Enterprise Value to EBITDA (EV/EBITDA)	37.31	28.73	0.00
Enterprise Value to EBIT (EV/EBIT)	200.03	246.05	0.00
Enterprise Value to NOPAT (EV/NOPAT)	606.13	463.83	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	38.04	38.52	17.78
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	50.60	54.06
Leverage & Solvency	-	-	-
Debt to Equity	0.55	0.47	1.52
Long-Term Debt to Equity	0.55	0.47	1.52
Financial Leverage	0.06	0.41	0.64
Leverage Ratio	1.64	1.74	2.06
Compound Leverage Factor	0.78	-0.15	2.10
Debt to Total Capital	35.67%	31.78%	60.39%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	35.67%	31.78%	60.39%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	64.33%	68.22%	39.61%
Debt to EBITDA	5.46	4.89	-0.93
Net Debt to EBITDA	4.23	4.01	-0.82
Long-Term Debt to EBITDA	5.46	4.89	-0.93
Debt to NOPAT	88.71	78.86	-1.16
Net Debt to NOPAT	68.66	64.70	-1.02
Long-Term Debt to NOPAT	88.71	78.86	-1.16
Altman Z-Score	3.11	2.72	-0.73
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	2.59	2.74	2.47
Quick Ratio	1.88	1.74	1.52
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-272	21	15
Operating Cash Flow to CapEx	885.00%	615.82%	1,719.24%
Free Cash Flow to Firm to Interest Expense	-70.10	4.47	2.55
Operating Cash Flow to Interest Expense	10.10	5.87	7.75
Operating Cash Flow Less CapEx to Interest Expense	8.96	4.91	7.30
Efficiency Ratios	-	-	-
Asset Turnover	0.28	0.32	0.39
Accounts Receivable Turnover	5.67	5.23	5.30
Inventory Turnover	4.21	2.88	2.46
Fixed Asset Turnover	7.28	7.72	7.22
Accounts Payable Turnover	12.17	12.17	13.62
Days Sales Outstanding (DSO)	64.36	69.79	68.89
Days Inventory Outstanding (DIO)	86.79	126.63	148.13
Days Payable Outstanding (DPO)	30.00	29.99	26.79
Cash Conversion Cycle (CCC)	121.15	166.43	190.23
Capital & Investment Metrics	-	-	-
Invested Capital	563	544	339
Invested Capital Turnover	0.43	0.40	0.49
Increase / (Decrease) in Invested Capital	275	-19	-205
Enterprise Value (EV)	1,492	1,078	785
Market Capitalization	1,323	928	591
Book Value per Share	$75.07	$73.60	$26.95
Tangible Book Value per Share	($28.11)	($20.53)	($27.52)
Total Capital	612	577	367
Total Debt	218	183	222
Total Long-Term Debt	218	183	222
Net Debt	169	150	193
Capital Expenditures (CapEx)	4.43	4.54	2.57
Debt-free, Cash-free Net Working Capital (DFCFNWC)	27	43	37
Debt-free Net Working Capital (DFNWC)	76	76	65
Net Working Capital (NWC)	76	76	65
Net Nonoperating Expense (NNE)	0.59	1.39	64
Net Nonoperating Obligations (NNO)	169	150	193
Total Depreciation and Amortization (D&A)	33	33	33
Debt-free, Cash-free Net Working Capital to Revenue	14.60%	19.49%	17.03%
Debt-free Net Working Capital to Revenue	41.37%	34.52%	30.09%
Net Working Capital to Revenue	41.37%	34.52%	30.09%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.36	$0.17	($47.20)
Adjusted Weighted Average Basic Shares Outstanding	5.21M	5.32M	5.39M
Adjusted Diluted Earnings per Share	$0.35	$0.17	($47.20)
Adjusted Weighted Average Diluted Shares Outstanding	5.34M	5.36M	5.39M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	5.27M	5.37M	5.41M
Normalized Net Operating Profit after Tax (NOPAT)	2.46	2.32	1.72
Normalized NOPAT Margin	1.34%	1.06%	0.80%
Pre Tax Income Margin	1.94%	-0.18%	-127.50%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	1.92	0.92	-47.38
NOPAT to Interest Expense	0.63	0.49	-33.43
EBIT Less CapEx to Interest Expense	0.78	-0.03	-47.84
NOPAT Less CapEx to Interest Expense	-0.51	-0.47	-33.88
Payout Ratios	-	-	-
Dividend Payout Ratio	178.46%	366.24%	-1.36%
Augmented Payout Ratio	178.46%	366.24%	-1.36%

This table displays calculated financial ratios and metrics derived from Mesa Laboratories' official financial filings.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	6/30/2022	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	44.48%	63.92%	-0.75%	-5.58%	0.38%	-9.50%	-1.50%	5.96%	14.86%	8.78%	17.52%
EBITDA Growth	-45.57%	31.32%	-279.82%	-20.53%	120.69%	-39.33%	229.61%	-2,908.62%	18.78%	73.94%	-52.36%
EBIT Growth	-291.88%	-14.18%	332.65%	-2.56%	102.52%	-109.13%	23.52%	-24,890.93%	3,098.20%	1,726.19%	-83.56%
NOPAT Growth	-173.19%	-55.18%	145.54%	570.00%	85.55%	-102.72%	-109.10%	-52,572.73%	1,141.57%	7,611.01%	5,652.69%
Net Income Growth	-172.08%	-64.89%	121.89%	134.25%	61.82%	-194.18%	369.18%	-41,766.61%	717.12%	378.70%	-179.21%
EPS Growth	-171.05%	-65.71%	120.51%	135.29%	62.96%	-195.83%	387.50%	-39,483.33%	720.00%	373.91%	-179.49%
Operating Cash Flow Growth	-129.31%	138.09%	-51.45%	34.58%	453.58%	-7.40%	49.46%	2.91%	4.97%	-46.08%	59.85%
Free Cash Flow Firm Growth	-4,650.35%	-3,457.26%	108.97%	107.04%	108.30%	106.38%	-336.02%	-22.10%	815.96%	1,067.24%	606.31%
Invested Capital Growth	89.49%	85.72%	-4.12%	-3.37%	-4.05%	-2.93%	10.46%	-37.69%	-36.99%	-34.57%	-47.35%
Revenue Q/Q Growth	-14.31%	16.44%	-7.60%	2.40%	-8.90%	4.98%	0.58%	10.16%	-1.25%	-0.58%	8.66%
EBITDA Q/Q Growth	-68.64%	238.68%	-178.36%	195.49%	-12.92%	-6.90%	67.42%	-2,690.64%	103.68%	36.34%	-54.15%
EBIT Q/Q Growth	-488.52%	204.55%	-33.06%	-64.17%	-89.94%	-478.38%	1,005.24%	-7,292.11%	101.30%	92.39%	-90.85%
NOPAT Q/Q Growth	-4,076.36%	147.94%	-48.06%	-54.81%	-228.43%	90.96%	-73.46%	-260,560.23%	102.55%	-34.84%	28.23%
Net Income Q/Q Growth	19.39%	190.82%	-65.47%	35.48%	-189.85%	-124.04%	272.03%	-12,131.33%	101.33%	1.18%	-148.89%
EPS Q/Q Growth	20.59%	188.89%	-66.67%	50.00%	-183.33%	-130.00%	269.57%	-12,217.95%	101.31%	1.61%	-149.21%
Operating Cash Flow Q/Q Growth	-130.22%	475.56%	-26.89%	62.21%	-20.61%	-1.64%	17.99%	11.69%	-19.02%	-49.48%	249.82%
Free Cash Flow Firm Q/Q Growth	3.77%	6.58%	109.88%	-20.79%	13.57%	-28.26%	-465.70%	126.14%	1,235.32%	-8.57%	58.63%
Invested Capital Q/Q Growth	-1.70%	-2.64%	2.13%	-1.15%	-2.39%	-1.50%	16.22%	-44.24%	-1.29%	2.27%	-6.47%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	62.12%	61.93%	60.36%	59.72%	61.57%	60.40%	62.47%	62.06%	64.03%	61.31%	63.26%
EBITDA Margin	7.40%	21.54%	-18.26%	17.03%	16.28%	14.44%	24.03%	-451.45%	16.84%	23.09%	9.74%
Operating Margin	-9.11%	6.80%	6.27%	0.93%	-1.31%	-0.11%	-0.13%	-460.55%	9.59%	6.07%	9.20%
EBIT Margin	-8.72%	7.83%	5.67%	1.98%	0.22%	-0.79%	7.11%	-464.22%	6.10%	11.81%	0.99%
Profit (Net Income) Margin	-2.85%	2.22%	0.83%	1.10%	-1.08%	-2.31%	3.96%	-432.20%	5.82%	5.93%	-2.67%
Tax Burden Percent	26.57%	38.59%	23.54%	-220.58%	58.59%	92.83%	108.74%	92.46%	86.76%	89.93%	75.60%
Interest Burden Percent	123.06%	73.60%	62.25%	-25.11%	-844.14%	315.48%	51.18%	100.69%	110.00%	55.81%	-354.72%
Effective Tax Rate	0.00%	61.41%	76.46%	0.00%	0.00%	0.00%	-8.74%	0.00%	13.24%	10.07%	0.00%
Return on Invested Capital (ROIC)	-3.01%	1.41%	0.58%	0.26%	-0.37%	-0.03%	-0.05%	-157.91%	4.30%	2.88%	3.30%
ROIC Less NNEP Spread (ROIC-NNEP)	2.39%	0.55%	0.38%	0.41%	-0.42%	-0.83%	1.14%	-195.54%	3.41%	3.05%	0.20%
Return on Net Nonoperating Assets (RNNOA)	0.20%	0.04%	0.16%	0.17%	-0.17%	-0.32%	0.53%	-124.77%	2.07%	1.76%	0.13%
Return on Equity (ROE)	-2.81%	1.45%	0.75%	0.43%	-0.55%	-0.36%	0.48%	-282.68%	6.38%	4.64%	3.43%
Cash Return on Invested Capital (CROIC)	-62.32%	-60.55%	4.54%	3.85%	4.73%	3.40%	-9.97%	3.29%	2.37%	-0.65%	23.33%
Operating Return on Assets (OROA)	-2.68%	2.76%	1.82%	0.63%	0.07%	-0.26%	2.15%	-181.05%	2.52%	4.94%	0.40%
Return on Assets (ROA)	-0.88%	0.78%	0.27%	0.35%	-0.36%	-0.76%	1.20%	-168.56%	2.41%	2.48%	-1.08%
Return on Common Equity (ROCE)	-2.81%	1.45%	0.75%	0.43%	-0.55%	-0.36%	0.48%	-282.68%	6.38%	4.64%	3.43%
Return on Equity Simple (ROE_SIMPLE)	-0.41%	-1.06%	-0.38%	0.00%	0.47%	-0.18%	0.24%	0.00%	-166.07%	-152.15%	-160.71%
Net Operating Profit after Tax (NOPAT)	-3.22	1.54	0.80	0.36	-0.46	-0.04	-0.07	-190	4.84	3.15	4.05
NOPAT Margin	-6.37%	2.62%	1.48%	0.65%	-0.92%	-0.08%	-0.14%	-322.39%	8.32%	5.45%	6.44%
Net Nonoperating Expense Percent (NNEP)	-5.40%	0.86%	0.21%	-0.16%	0.05%	0.79%	-1.19%	37.62%	0.89%	-0.17%	3.10%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-0.01%	-	-	-	1.15%
Cost of Revenue to Revenue	37.88%	38.07%	39.64%	40.28%	38.43%	39.61%	37.53%	37.94%	35.97%	38.69%	36.74%
SG&A Expenses to Revenue	59.93%	46.64%	45.25%	49.79%	53.38%	51.12%	54.56%	47.71%	46.30%	47.23%	46.02%
R&D to Revenue	11.30%	8.49%	8.84%	9.00%	9.50%	9.39%	8.03%	8.83%	8.14%	8.01%	8.04%
Operating Expenses to Revenue	71.22%	55.13%	54.09%	58.79%	62.88%	60.51%	62.59%	522.61%	54.44%	55.24%	54.07%
Earnings before Interest and Taxes (EBIT)	-4.40	4.60	3.08	1.10	0.11	-0.42	3.80	-273	3.55	6.83	0.63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3.74	13	-9.92	9.47	8.25	7.68	13	-266	9.79	13	6.12
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.80	1.98	2.27	2.36	1.77	1.45	1.39	4.07	3.11	4.35	4.61
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	5.32	3.33	3.96	4.23	3.13	2.63	2.64	2.73	2.10	3.08	3.01
Price to Earnings (P/E)	0.00	0.00	0.00	997.39	377.12	0.00	592.62	0.00	0.00	0.00	0.00
Dividend Yield	0.32%	0.46%	0.39%	0.37%	0.50%	0.61%	0.61%	0.58%	0.74%	0.49%	0.49%
Earnings Yield	0.00%	0.00%	0.00%	0.10%	0.27%	0.00%	0.17%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.24	1.68	1.90	1.98	1.56	1.33	1.26	2.32	1.95	2.58	2.75
Enterprise Value to Revenue (EV/Rev)	6.19	4.07	4.69	4.92	3.78	3.26	3.60	3.63	2.92	3.87	3.71
Enterprise Value to EBITDA (EV/EBITDA)	162.87	85.44	26.10	28.73	138.58	0.00	20.05	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	1,608.13	100,734.97	236.49	246.05	93.26	180.14	166.79	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	553.24	463.83	256.88	311.86	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	46.10	27.52	42.11	38.52	20.35	17.46	17.51	17.78	14.64	22.01	18.73
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	40.90	50.60	32.32	38.67	0.00	54.06	63.66	0.00	8.14
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.57	0.53	0.49	0.47	0.45	0.44	0.58	1.52	1.41	1.27	1.26
Long-Term Debt to Equity	0.57	0.53	0.49	0.47	0.45	0.44	0.58	1.52	1.38	0.65	0.61
Financial Leverage	0.08	0.07	0.43	0.41	0.41	0.39	0.47	0.64	0.61	0.57	0.66
Leverage Ratio	1.67	1.64	1.77	1.74	1.73	1.70	1.78	2.06	2.01	1.99	2.11
Compound Leverage Factor	2.05	1.20	1.10	-0.44	-14.60	5.35	0.91	2.07	2.21	1.11	-7.49
Debt to Total Capital	36.28%	34.47%	32.81%	31.78%	31.16%	30.57%	36.63%	60.39%	58.47%	55.94%	55.77%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.03%	27.50%	28.76%
Long-Term Debt to Total Capital	36.28%	34.47%	32.81%	31.78%	31.16%	30.57%	36.63%	60.39%	57.44%	28.44%	27.01%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	63.72%	65.53%	67.19%	68.22%	68.84%	69.43%	63.37%	39.61%	41.53%	44.06%	44.23%
Debt to EBITDA	28.53	18.55	4.73	4.89	29.33	-27.63	6.09	-0.93	-0.90	-0.89	-0.83
Net Debt to EBITDA	22.76	15.50	4.08	4.01	23.92	-21.87	5.35	-0.82	-0.78	-0.79	-0.70
Long-Term Debt to EBITDA	28.53	18.55	4.73	4.89	29.33	-27.63	6.09	-0.93	-0.89	-0.45	-0.40
Debt to NOPAT	-102.63	-87.29	100.28	78.86	54.38	76.34	-1,214.62	-1.16	-1.14	-1.12	-1.09
Net Debt to NOPAT	-81.90	-72.93	86.44	64.70	44.35	60.41	-1,067.47	-1.02	-0.99	-0.98	-0.92
Long-Term Debt to NOPAT	-102.63	-87.29	100.28	78.86	54.38	76.34	-1,214.62	-1.16	-1.12	-0.57	-0.53
Altman Z-Score	2.66	2.24	2.55	2.70	2.26	1.99	1.55	-0.76	1.07	1.32	1.37
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.90	2.80	2.74	2.74	2.93	2.96	2.68	2.47	1.94	0.70	0.71
Quick Ratio	1.94	1.79	1.65	1.74	1.74	1.81	1.45	1.52	1.17	0.42	0.45
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-265	-247	24	19	22	16	-58	15	201	184	292
Operating Cash Flow to CapEx	-1,249.33%	644.11%	466.63%	1,220.18%	3,681.11%	1,541.96%	1,022.61%	2,408.04%	1,170.93%	294.80%	2,268.02%
Free Cash Flow to Firm to Interest Expense	-260.85	-203.54	21.01	14.01	20.96	17.41	-31.05	7.98	0.00	60.95	102.66
Operating Cash Flow to Interest Expense	-2.77	8.70	6.64	9.07	9.48	10.80	6.22	6.82	0.00	1.75	6.49
Operating Cash Flow Less CapEx to Interest Expense	-2.99	7.35	5.22	8.33	9.23	10.10	5.61	6.54	0.00	1.15	6.20
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.31	0.35	0.32	0.32	0.33	0.33	0.30	0.39	0.41	0.42	0.40
Accounts Receivable Turnover	6.40	6.91	5.58	5.23	5.66	5.47	5.43	5.30	6.29	5.96	6.37
Inventory Turnover	4.19	4.55	3.02	2.88	2.75	2.77	2.38	2.46	2.51	2.74	2.77
Fixed Asset Turnover	8.00	8.80	7.61	7.72	7.84	7.52	7.09	7.22	7.54	7.53	7.50
Accounts Payable Turnover	14.07	14.97	12.29	12.17	13.04	13.46	15.31	13.62	15.01	15.88	20.54
Days Sales Outstanding (DSO)	56.99	52.79	65.40	69.79	64.45	66.74	67.23	68.89	58.05	61.19	57.32
Days Inventory Outstanding (DIO)	87.16	80.26	120.86	126.63	132.90	131.68	153.32	148.13	145.59	133.32	131.83
Days Payable Outstanding (DPO)	25.93	24.39	29.69	29.99	27.98	27.12	23.85	26.79	24.32	22.99	17.77
Cash Conversion Cycle (CCC)	118.23	108.67	156.57	166.43	169.36	171.30	196.70	190.23	179.32	171.52	171.37
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	553	539	550	544	531	523	608	339	335	342	320
Invested Capital Turnover	0.47	0.54	0.40	0.40	0.40	0.40	0.37	0.49	0.52	0.53	0.51
Increase / (Decrease) in Invested Capital	261	249	-24	-19	-22	-16	58	-205	-196	-181	-288
Enterprise Value (EV)	1,237	907	1,043	1,078	829	697	767	785	653	883	881
Market Capitalization	1,064	742	880	928	686	562	562	591	469	702	716
Book Value per Share	$72.22	$70.38	$72.55	$73.60	$72.20	$72.02	$74.74	$26.95	$27.87	$29.85	$28.58
Tangible Book Value per Share	($26.22)	($23.70)	($22.87)	($20.53)	($18.89)	($17.31)	($32.64)	($27.52)	($25.60)	($24.24)	($22.12)
Total Capital	597	571	576	577	563	558	636	367	363	366	351
Total Debt	217	197	189	183	176	171	233	222	212	205	196
Total Long-Term Debt	217	197	189	183	176	171	233	222	208	104	95
Net Debt	173	164	163	150	143	135	205	193	184	181	165
Capital Expenditures (CapEx)	0.23	1.64	1.65	1.03	0.27	0.63	1.13	0.54	0.89	1.79	0.81
Debt-free, Cash-free Net Working Capital (DFCFNWC)	40	42	46	43	43	42	46	37	27	31	25
Debt-free Net Working Capital (DFNWC)	84	75	73	76	76	78	74	65	56	56	56
Net Working Capital (NWC)	84	75	73	76	76	78	74	65	52	-45	-45
Net Nonoperating Expense (NNE)	-1.78	0.24	0.35	-0.25	0.08	1.19	-2.19	65	1.45	-0.27	5.72
Net Nonoperating Obligations (NNO)	173	164	163	150	143	135	205	193	184	181	165
Total Depreciation and Amortization (D&A)	8.13	8.06	-13	8.37	8.13	8.10	9.05	7.52	6.24	6.52	5.50
Debt-free, Cash-free Net Working Capital to Revenue	20.14%	19.02%	20.90%	19.49%	19.75%	19.76%	21.58%	17.03%	12.12%	13.66%	10.48%
Debt-free Net Working Capital to Revenue	42.03%	33.56%	32.63%	34.52%	34.52%	36.43%	34.84%	30.09%	24.84%	24.31%	23.50%
Net Working Capital to Revenue	42.03%	33.56%	32.63%	34.52%	34.52%	36.43%	34.84%	30.09%	23.17%	-19.81%	-18.94%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.27)	$0.25	$0.08	$0.11	($0.10)	($0.23)	$0.39	($47.26)	$0.63	$0.63	($0.31)
Adjusted Weighted Average Basic Shares Outstanding	5.27M	5.32M	5.34M	5.32M	5.37M	5.39M	5.39M	5.39M	5.40M	5.41M	5.43M
Adjusted Diluted Earnings per Share	($0.27)	$0.24	$0.08	$0.12	($0.10)	($0.23)	$0.39	($47.26)	$0.62	$0.63	($0.31)
Adjusted Weighted Average Diluted Shares Outstanding	5.27M	5.36M	5.36M	5.36M	5.37M	5.39M	5.40M	5.39M	5.42M	5.47M	5.43M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	5.32M	5.34M	5.35M	5.37M	5.38M	5.39M	5.39M	5.41M	5.41M	5.43M	5.43M
Normalized Net Operating Profit after Tax (NOPAT)	-3.22	2.80	2.38	0.36	-0.46	-0.04	-0.05	-190	4.84	3.15	4.05
Normalized NOPAT Margin	-6.37%	4.76%	4.39%	0.65%	-0.92%	-0.08%	-0.09%	-322.39%	8.32%	5.45%	6.44%
Pre Tax Income Margin	-10.73%	5.76%	3.53%	-0.50%	-1.85%	-2.49%	3.64%	-467.43%	6.71%	6.59%	-3.53%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-4.34	3.79	2.65	0.80	0.11	-0.46	2.05	-144.83	0.00	2.26	0.22
NOPAT to Interest Expense	-3.17	1.27	0.69	0.26	-0.44	-0.05	-0.04	-100.58	0.00	1.05	1.42
EBIT Less CapEx to Interest Expense	-4.56	2.44	1.23	0.06	-0.15	-1.16	1.44	-145.12	0.00	1.67	-0.07
NOPAT Less CapEx to Interest Expense	-3.39	-0.08	-0.73	-0.48	-0.70	-0.75	-0.65	-100.87	0.00	0.45	1.14
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-214.98%	-84.91%	-231.67%	366.24%	188.13%	-478.66%	362.76%	-1.36%	-1.38%	-1.41%	-1.39%
Augmented Payout Ratio	-214.98%	-84.91%	-231.67%	366.24%	188.13%	-478.66%	362.76%	-1.36%	-1.38%	-1.41%	-1.39%

Frequently Asked Questions About Mesa Laboratories' Financials

When does Mesa Laboratories's financial year end?

According to the most recent income statement we have on file, Mesa Laboratories' fiscal year ends in March. Their fiscal year 2024 ended on March 31, 2024.

How has Mesa Laboratories' net income changed over the last 2 years?

Mesa Laboratories' net income appears to be on an upward trend, with a most recent value of -$254.25 million in 2024, falling from $1.87 million in 2022. The previous period was $930 thousand in 2023. See where experts think Mesa Laboratories is headed by visiting Mesa Laboratories' forecast page.

What is Mesa Laboratories's operating income?

Mesa Laboratories's total operating income in 2024 was -$272.08 million, based on the following breakdown:

Total Gross Profit: $133.25 million
Total Operating Expenses: $405.33 million

How has Mesa Laboratories revenue changed over the last 2 years?

Over the last 2 years, Mesa Laboratories' total revenue changed from $184.34 million in 2022 to $216.19 million in 2024, a change of 17.3%.

How much debt does Mesa Laboratories have?

Mesa Laboratories' total liabilities were at $301.40 million at the end of 2024, a 12.3% increase from 2023, and a 3.9% decrease since 2022.

How much cash does Mesa Laboratories have?

In the past 2 years, Mesa Laboratories' cash and equivalents has ranged from $28.21 million in 2024 to $49.35 million in 2022, and is currently $28.21 million as of their latest financial filing in 2024.

How has Mesa Laboratories' book value per share changed over the last 2 years?

Over the last 2 years, Mesa Laboratories' book value per share changed from 75.07 in 2022 to 26.95 in 2024, a change of -64.1%.

Related Companies

This page (NASDAQ:MLAB) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mesa Laboratories (MLAB) Financials

Frequently Asked Questions About Mesa Laboratories' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mesa Laboratories (MLAB) Financials

Annual Income Statements for Mesa Laboratories

Quarterly Income Statements for Mesa Laboratories

Annual Cash Flow Statements for Mesa Laboratories

Quarterly Cash Flow Statements for Mesa Laboratories

Annual Balance Sheets for Mesa Laboratories

Quarterly Balance Sheets for Mesa Laboratories

Annual Metrics and Ratios for Mesa Laboratories

Quarterly Metrics and Ratios for Mesa Laboratories

Frequently Asked Questions About Mesa Laboratories' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools